Aquestive Therapeutics, Inc. AQST Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s deferred revenue?
- Aquestive Therapeutics, Inc. (AQST) reported deferred revenue of $1.09M in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s deferred revenue changed year-over-year?
- Aquestive Therapeutics, Inc.'s deferred revenue increased by 4.2% year-over-year, from $1.05M to $1.09M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s deferred revenue?
- Over 5 years (2020 to 2025), Aquestive Therapeutics, Inc.'s deferred revenue has grown at a 9.5% compound annual growth rate (CAGR), from $693K to $1.09M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.